YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
YD Bio Ltd (YDES) - Net Assets
Latest net assets as of June 2025: $-16.05 Million USD
Based on the latest financial reports, YD Bio Ltd (YDES) has net assets worth $-16.05 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.95 Million) and total liabilities ($19.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-16.05 Million |
| % of Total Assets | -543.81% |
| Annual Growth Rate | -49.3% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12393.25 |
YD Bio Ltd - Net Assets Trend (2020–2024)
This chart illustrates how YD Bio Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for YD Bio Ltd (2020–2024)
The table below shows the annual net assets of YD Bio Ltd from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.59 Million | +28560.72% |
| 2023-12-31 | $22.99K | -99.79% |
| 2022-12-31 | $11.20 Million | -89.72% |
| 2021-12-31 | $108.96 Million | +9.20% |
| 2020-12-31 | $99.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to YD Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1329724200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $144.18K | 2.19% |
| Other Comprehensive Income | $45.07K | 0.68% |
| Other Components | $8.33 Million | 126.37% |
| Total Equity | $6.59 Million | 100.00% |
YD Bio Ltd Competitors by Market Cap
The table below lists competitors of YD Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kardan NV
TA:KRNV
|
$57.69K |
|
ENVIROMETAL TECHN. O.N.
F:7N20
|
$57.71K |
|
SILO WELLNESS INC.
F:3K7A
|
$57.71K |
|
ABP NOCIVELLI O.N.
F:9UZ
|
$57.73K |
|
Advanced Medical Solutions Group plc
LSE:AMS
|
$57.66K |
|
Plantx Life Inc.
PINK:PLTXF
|
$57.65K |
|
Lenskart Solutions Ltd
NSE:LENSKART
|
$57.62K |
|
Agroliga Group PLC
WAR:AGL
|
$57.60K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in YD Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,994 to 6,590,246, a change of 6,567,252 (28560.7%).
- Net loss of 1,411,559 reduced equity.
- New share issuances of 7,860,181 increased equity.
- Other comprehensive income decreased equity by 2,139.
- Other factors increased equity by 120,769.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.41 Million | -21.42% |
| Share Issuances | $7.86 Million | +119.27% |
| Other Comprehensive Income | $-2.14K | -0.03% |
| Other Changes | $120.77K | +1.83% |
| Total Change | $- | 28560.72% |
Book Value vs Market Value Analysis
This analysis compares YD Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.93x to 3.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $6.82 | $6.34 | x |
| 2021-12-31 | $7.45 | $6.34 | x |
| 2022-12-31 | $1.20 | $6.34 | x |
| 2023-12-31 | $0.00 | $6.34 | x |
| 2024-12-31 | $1.59 | $6.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently YD Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -276.58%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.04x
- Recent ROE (-21.42%) is below the historical average (15.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.54% | 0.00% | 0.00x | 1.18x | $-12.52 Million |
| 2021 | 7.99% | 0.00% | 0.00x | 1.08x | $-2.19 Million |
| 2022 | 33.83% | 0.00% | 0.00x | 1.60x | $2.67 Million |
| 2023 | 58.97% | 3.87% | 1.09x | 13.97x | $11.26K |
| 2024 | -21.42% | -276.58% | 0.07x | 1.04x | $-2.07 Million |
Industry Comparison
This section compares YD Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| YD Bio Ltd (YDES) | $-16.05 Million | -2.54% | N/A | $57.66K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |